Welcome to our dedicated page for Sunshine Biopharma news (Ticker: SBFM), a resource for investors and traders seeking the latest updates and insights on Sunshine Biopharma stock.
Sunshine Biopharma Inc. reports developments as a pharmaceutical company with commercial generic prescription drugs in Canada and proprietary drug-development programs in oncology and antivirals. News commonly covers product launches through its Nora Pharma subsidiary, including generic medicines such as Domperidone, Doxycycline and Pravastatin, as well as Health Canada commercialization approvals and expansion of therapeutic categories.
The company’s updates also address financial results, portfolio growth and research programs including K1.1 mRNA, an mRNA-lipid nanoparticle candidate targeting liver cancer, and a PLpro protease inhibitor for SARS-related coronavirus infections. Corporate and treasury actions may appear alongside operating updates when they affect Sunshine Biopharma’s capital strategy or public-company profile.
Sunshine Biopharma (OTC PINK: SBFM) has expanded its board from three to five members by appointing three new independent directors: Andrew Tesley, JD Kish, and Dr. Rabi Kiderchah. This strategic move is part of the company's application process to uplist to Nasdaq. The new directors bring valuable expertise in legal, accounting, and medical fields. Mr. Camille Sebaaly has resigned as a director but will continue as CFO. Sunshine Biopharma is advancing treatments for COVID-19 and cancer, including ongoing studies on potential inhibitors of SARS-CoV-2 and the anticancer drug Adva-27a.
Sunshine Biopharma (SBFM) has filed a patent application for a novel treatment targeting neurodegenerative disorders. This application, dated October 1, 2021, presents data indicating that specific mRNA molecules can protect neuronal cells from oxidative stress, a condition mimicking neuronal degeneration. Neurodegenerative diseases affect millions globally, with no known cures. The company aims to develop a therapeutic approach that could potentially alleviate symptoms and halt disease progression.
Sunshine Biopharma (SBFM) announced significant advancements in its drug development for COVID-19 and cancer therapies. The company mapped mutations from Delta and other variants, finding that most mutations affect the Spike protein, leaving their PLpro inhibitors likely effective against ongoing variants. The lead compound, SBFM-PL4, is being tested in mice engineered to be susceptible to SARS-CoV-2. Additionally, Sunshine Biopharma is progressing with Adva-27a, an anticancer compound, demonstrating effectiveness against multidrug-resistant cancer cells. Clinical trials for pancreatic cancer are planned.
Sunshine Biopharma (SBFM) has launched an official Twitter account (@SunshineBio1) to enhance communication with shareholders, following feedback regarding preferred engagement methods. The company aims to utilize this platform for timely updates, recognizing the importance of transparency in modern information dissemination. Sunshine Biopharma is advancing potential Covid-19 treatments and developing the anticancer compound Adva-27a. While the company emphasizes shareholder engagement, it also acknowledges the inherent risks and uncertainties in meeting financial expectations and achieving profitability.
Sunshine Biopharma (SBFM) has secured $900,000 in additional funding from RB Capital Partners, bringing total investments to over $3.5 million. This convertible debt has a conversion price of $0.30 per share. The funds will boost the development of its COVID-19 protease inhibitor and the anticancer drug Adva-27a. The company is advancing treatments targeting SARS-CoV-2 and is preparing for clinical trials related to pancreatic cancer at McGill University. Despite the progress, Sunshine Biopharma cautions of various risks impacting growth and profitability.
Sunshine Biopharma (SBFM) has reported a breakthrough in cancer therapy by inhibiting Nrf2 using mRNA vaccine technology. This inhibition could lead to enhanced effectiveness of anticancer drugs like Etoposide, demonstrating a 4-fold increase in activity against multidrug-resistant cancer cells. Additionally, the company is developing anti-COVID-19 treatments, with its lead compound SBFM-PL4 undergoing testing in genetically modified mice. Sunshine Biopharma also plans clinical trials for its anticancer drug Adva-27a at McGill University, targeting pancreatic cancer.
Sunshine Biopharma (SBFM) announced progress in its COVID-19 study at the University of Georgia, focusing on two protease inhibitors aimed at preventing illness in transgenic mice exposed to SARS-CoV-2. Successful results may lead to FDA testing in human patients. The company is also developing Adva-27a, an anticancer drug effective against multidrug-resistant cancer cells, with clinical trials planned at McGill University. The ongoing projects highlight Sunshine Biopharma's commitment to advancing innovative treatment options amidst the COVID-19 pandemic.
Sunshine Biopharma (SBFM) announced the elucidation of the mechanism of action of their anticancer drug candidate, Adva-27a. Notably, Adva-27a evades P-glycoprotein, a key player in multidrug resistance in over 50% of cancer cases, and inhibits Topoisomerase II, allowing it to effectively destroy both drug-sensitive and drug-resistant cancer cells. Additionally, the company is developing SBFM-PL4, a potential oral treatment for COVID-19, in collaboration with the University of Georgia. Clinical trials for Adva-27a in pancreatic cancer are planned at McGill University's Jewish General Hospital.
Sunshine Biopharma (SBFM) has eliminated $250,000 in variable rate convertible debt, enhancing its financial standing. The necessary debt elimination paves the way for a re-application to uplist to the OTCQB in October 2021, after a prior rejection due to outstanding loans. CFO Camille Sebaaly emphasized the importance of protecting shareholders from dilution. With funding from RB Capital Partners, SBFM aims to remove all harmful debts, thus improving its balance sheet. The company continues to develop potential COVID-19 treatments and an anti-cancer compound, Adva-27a.
Sunshine Biopharma (SBFM) reported its Q1 2021 financials, showing Cash & Cash Equivalents of $1,796,596 as of March 31, 2021. Notable developments include a Notice of Allowance from the Canadian Intellectual Property Office for a new patent on Adva-27a, extending protection until 2033, and an exclusive licensing agreement with the University of Georgia for two Anti-Coronavirus compounds. The company launched a new eCommerce site selling over 20 nutritional products, all manufactured in Canada under GMP standards.